Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by Los Angeles Capital Management LLC

Los Angeles Capital Management LLC lowered its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 82.6% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 2,959 shares of the biopharmaceutical company’s stock after selling 14,069 shares during the quarter. Los Angeles Capital Management LLC’s holdings in Alnylam Pharmaceuticals were worth $442,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. boosted its position in Alnylam Pharmaceuticals by 2.5% during the fourth quarter. Vanguard Group Inc. now owns 11,943,895 shares of the biopharmaceutical company’s stock worth $2,286,181,000 after acquiring an additional 287,064 shares during the last quarter. V Square Quantitative Management LLC purchased a new position in Alnylam Pharmaceuticals during the fourth quarter worth approximately $52,000. Eventide Asset Management LLC purchased a new position in Alnylam Pharmaceuticals during the fourth quarter worth approximately $16,653,000. Oracle Alpha Inc. purchased a new position in Alnylam Pharmaceuticals during the fourth quarter worth approximately $404,000. Finally, Bridger Management LLC purchased a new position in Alnylam Pharmaceuticals during the fourth quarter worth approximately $3,622,000. Institutional investors and hedge funds own 92.97% of the company’s stock.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, Director Amy W. Schulman sold 21,700 shares of the company’s stock in a transaction dated Wednesday, May 29th. The shares were sold at an average price of $148.60, for a total value of $3,224,620.00. Following the completion of the transaction, the director now owns 8,436 shares in the company, valued at approximately $1,253,589.60. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 1.50% of the stock is owned by insiders.

Alnylam Pharmaceuticals Price Performance

Shares of ALNY stock opened at $240.15 on Wednesday. Alnylam Pharmaceuticals, Inc. has a 1-year low of $141.98 and a 1-year high of $242.00. The firm has a fifty day moving average of $153.86 and a two-hundred day moving average of $163.08. The firm has a market cap of $30.38 billion, a P/E ratio of -89.61 and a beta of 0.30.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.23. The business had revenue of $494.33 million during the quarter, compared to analyst estimates of $428.01 million. During the same period last year, the firm posted ($1.40) earnings per share. The company’s quarterly revenue was up 54.8% on a year-over-year basis. On average, sell-side analysts expect that Alnylam Pharmaceuticals, Inc. will post -3.74 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on ALNY shares. BMO Capital Markets reaffirmed an “outperform” rating and set a $234.00 price target on shares of Alnylam Pharmaceuticals in a research note on Monday. Chardan Capital reissued a “buy” rating and issued a $225.00 target price on shares of Alnylam Pharmaceuticals in a research note on Friday, May 3rd. Wells Fargo & Company raised their target price on shares of Alnylam Pharmaceuticals from $161.00 to $207.00 and gave the company an “equal weight” rating in a research note on Tuesday. Canaccord Genuity Group reissued a “buy” rating and issued a $283.00 target price on shares of Alnylam Pharmaceuticals in a research note on Friday, June 21st. Finally, Needham & Company LLC raised their target price on shares of Alnylam Pharmaceuticals from $200.00 to $275.00 and gave the company a “buy” rating in a research note on Monday. Eight analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $242.52.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.